A detailed history of Sg Americas Securities, LLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 30,612 shares of AVIR stock, worth $97,652. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,612
Previous 14,051 117.86%
Holding current value
$97,652
Previous $47,000 119.15%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$3.17 - $4.02 $52,498 - $66,575
16,561 Added 117.86%
30,612 $103,000
Q2 2024

Jul 12, 2024

SELL
$3.31 - $4.04 $46,634 - $56,919
-14,089 Reduced 50.07%
14,051 $47,000
Q1 2024

May 06, 2024

SELL
$3.09 - $4.56 $44,437 - $65,577
-14,381 Reduced 33.82%
28,140 $114,000
Q4 2023

Jan 12, 2024

BUY
$2.8 - $3.35 $22,467 - $26,880
8,024 Added 23.26%
42,521 $130,000
Q3 2023

Oct 13, 2023

BUY
$3.0 - $3.79 $103,491 - $130,743
34,497 New
34,497 $103,000
Q1 2023

Apr 28, 2023

SELL
$3.0 - $4.97 $23,589 - $39,079
-7,863 Reduced 20.14%
31,179 $104,000
Q4 2022

Feb 02, 2023

SELL
$4.35 - $6.17 $173,116 - $245,547
-39,797 Reduced 50.48%
39,042 $188,000
Q3 2022

Oct 31, 2022

BUY
$5.49 - $8.79 $74,219 - $118,832
13,519 Added 20.7%
78,839 $449,000
Q2 2022

Jul 29, 2022

BUY
$5.33 - $8.18 $348,155 - $534,317
65,320 New
65,320 $464,000
Q1 2022

Apr 29, 2022

SELL
$5.5 - $9.19 $95,485 - $159,547
-17,361 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$7.67 - $44.59 $155,877 - $906,202
-20,323 Reduced 53.93%
17,361 $155,000
Q3 2021

Nov 01, 2021

BUY
$21.33 - $35.06 $803,799 - $1.32 Million
37,684 New
37,684 $1.32 Million
Q2 2021

Aug 12, 2021

SELL
$19.22 - $59.08 $40,727 - $125,190
-2,119 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$41.42 - $88.44 $87,768 - $187,404
2,119 New
2,119 $131,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $266M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.